Company Description
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally.
It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software.
In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients.
The company offers its products directly to customers, as well as through third-party distributors and sub-distributors.
It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss.
The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
| Country | United States |
| IPO Date | Jul 17, 2014 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 643 |
| CEO | John Walter Hanna Jr. |
Contact Details
Address: 8000 Marina Blvd, 4th Floor Brisbane, California 94005 United States | |
| Phone | 415-287-2300 |
| Website | caredx.com |
Stock Details
| Ticker Symbol | CDNA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001217234 |
| CUSIP Number | 14167L103 |
| ISIN Number | US14167L1035 |
| Employer ID | 94-3316839 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Abhishek Jain | Chief Financial Officer and Principal Accounting Officer |
| Dr. Peter Maag Ph.D. | Executive Director |
| Alexander L. Johnson | President of Patient and Testing Services |
| Marica Grskovic Ph.D. | Chief Operating Officer |
| Dr. Robert N. Woodward Ph.D. | Chief Scientific Officer |
| GS Jha | Senior Vice President, Chief Information Officer and Chief Information Security Officer |
| Jeffrey A. Novack | General Counsel |
| Stacey Follon | Senior Vice President and Head of Human Resources |
| Kashif Rathore | Chief of Patient and Digital Solutions |
| Hal Gibson | Senior Vice President of Strategic Planning |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 21, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 18, 2024 | 8-K | Current Report |
| May 23, 2024 | EFFECT | Notice of Effectiveness |
| May 23, 2024 | POS AM | Post-Effective amendments for registration statement |
| May 9, 2024 | POS AM | Post-Effective amendments for registration statement |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| Apr 30, 2024 | ARS | Filing |
| Apr 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2024 | DEF 14A | Other definitive proxy statements |